BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • BioTech Events
  • BioTech Company Directory
  • Contact Us
Archives
  • September 2022
  • August 2022
  • July 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • BioTech Events
  • BioTech Company Directory
  • Contact Us

Browsing Tag

Tuksya

1 post

TUKYSA is a prescription medicine used with the medicines trastuzumab and capecitabine to treat adults with human epidermal growth factor receptor-2 (HER2) positive breast cancer that has spread to other parts of the body such as the brain (metastatic), or that cannot be removed by surgery, and who have received one or more anti-HER2 breast cancer treatments.

Recent Report Highlights Success in FDA Subgroup Approval & Treatment Arm Data
BioTech Health X
  • July 27, 2021

Biotech NewsRecent Report Highlights Success in FDA Subgroup Approval & Treatment Arm Data

  • 9 minute read
A recent report published by the American Association for Cancer Research titled Subgroup Analyses in Oncology Trials: Regulatory…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • Virios Therapeutics Stock Plunges 70% on Fibromyalgia Clinical Trial Failure Results
  • CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022
  • Mayo Clinic, Hibiscus BioVentures, and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator
  • SyneuRx CEO Dr. Emil Tsai Exclusive Interview with Insights & Projections
  • Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
Recent Comments
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • September 19, 2022
    Virios Therapeutics Stock Plunges 70% on Fibromyalgia Clinical Trial Failure Results
    Virios-Therapeutics-Stock-Plunges-70-on-Fibromyalgia-Clinical-Trial-Failure-Results
    • September 14, 2022
    CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022
    CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022
    • September 3, 2022
    Mayo Clinic, Hibiscus BioVentures, and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator
    Mayo-Clinic-Gene-Accelerator
    • September 2, 2022
    SyneuRx CEO Dr. Emil Tsai Exclusive Interview with Insights & Projections
    SyneuRx CEO Interview Dr Emil Tsai BioTech Health X
    • August 1, 2022
    Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
    Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
Recent Posts
  • ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug
    ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug
    • July 28, 2022
  • Brickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement
    Brickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement
    • July 22, 2022
  • Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
    Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
    • July 20, 2022
Categories
  • BioTech CEO Interviews (4)
  • Biotech News (44)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by Code Supply Co.
  • Our Contributors
  • List of Modern Life Science Technologies
  • Contact Us
Back to top